NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.